Abbott Prevails In $219M Whistleblower FCA Trial
By Jess Krochtengel · April 7, 2016, 5:58 PM EDT
A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219...
To view the full article, register now.